Article Sidebar

PDF
Date Published: 15/02/2023
Abstract Views: 554
Views PDF: 161
DOI: https://doi.org/10.51298/vmj.v521i2.4070
Issue
Vol. 521 No. 2 (2022)
Section
Các bài báo
How to Cite
Hoàng, V. K. ., Nguyễn, T. L. M., Bùi, V. N., Nguyễn, Đỗ Q., Đoàn, Đức D., & Nguyễn, L. H. . (2023). ASSESSMENT THE H2FPEF SCORE IN HYPERTENSIVE PATIENTS WITH UNEXPLAINED DYSPNEA. Vietnam Medical Journal, 521(2). https://doi.org/10.51298/vmj.v521i2.4070

ASSESSMENT THE H2FPEF SCORE IN HYPERTENSIVE PATIENTS WITH UNEXPLAINED DYSPNEA

Văn Kỳ Hoàng1,2,, Thị Lý Minh Nguyễn1,3, Văn Nhơn Bùi2,4, Đỗ Quân Nguyễn4, Đức Dũng Đoàn4, Lân Hiếu Nguyễn3,4
1 Hanoi Medical university hospital
2 Hanoi medical university
3 hanoi medical university
4 Hanoi medical university hospital

Main Article Content

Abstract

Aims: The study aimed to investigate the H2FPEF SCORE in hypertensive patients with unexplained dyspnea and have a ejection fraction (EF) ≥ 50% at the outpatient clinics. Results: the average H2FPEF SCORE was 2.75 ± 1.42, the highest was 7 points, the lowest was 0 points. According to each scale factor, the proportion of patients with obesity (BMI > 30 kg/m²) accounted for only 2.2%, atrial fibrillation accounted for 10.4%. The H2FPEF SCORE was higher in the group with chronic kidney disease (p=0.05). The NT-pro BNP index was statistically significantly higher in the group of patients with high H2FPEF score (p<0.001). Left atrial volume index (LAVI) increased in proportion to high H2FPEF score (p < 0.001). Conclusion: the average H2FPEF SCORE is lower than other studies due to lower average BMI, a lower prevalence of obesity, atrial fibrillation (two important factors in the scale. Chronic kidney disease, NT-proBNP, and left atrial volume index (LAVI) were strongly associated with H2FPEF scores.

Article Details

Keywords

H2FPEF SCORE, heart failure with preserved ejection fraction, hypertension, EF≥50%.

References

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021; 42(36): 3599-3726. doi: 10.1093/ eurheartj/ ehab368
2. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297-3317. doi:10.1093/eurheartj/ehz641
3. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861-870. doi:10.1161/CIRCULATIONAHA.118.034646
4. Suzuki S, Kaikita K, Yamamoto E, et al. H2FPEF score for predicting future heart failure in stable outpatients with cardiovascular risk factors. ESC Heart Failure. 2020; 7(1):66-75. doi: 10.1002/ehf2.12570
5. Faxen UL, Venkateshvaran A, Shah SJ, et al. Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. Journal of Cardiac Failure. 2021; 27(7): 756-765. doi: 10.1016/ j.cardfail. 2021.02.005
6. Unger ED, Dubin RF, Deo R, et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction: CKD and cardiac mechanics in HFpEF. Eur J Heart Fail. 2016;18(1):103-112. doi:10.1002/ejhf.445
7. Mavrakanas TA, Khattak A, Wang W, Singh K, Charytan DM. Association of Chronic Kidney Disease with Preserved Ejection Fraction Heart Failure Is Independent of Baseline Cardiac Function. Kidney Blood Press Res. 2019; 44(5):1247-1258. doi:10.1159/000502874
8. Sueta D, Yamamoto E, Nishihara T, et al. H2FPEF Score as a Prognostic Value in HFpEF Patients. American Journal of Hypertension. 2019; 32(11):1082-1090. doi:10.1093/ajh/hpz108